经颈动脉与经心尖及经主动脉途径TAVR的比较
该回顾性研究纳入165例接受替代途径TAVR的患者,比较经颈动脉(84例)、经心尖(48例)和经主动脉(33例)途径的30天结局及2年生存。经颈动脉途径与更短住院时间、更低输血率、更高出院回家率及更好2年生存相关,30天卒中率相似。
要点
- 经颈动脉TAVR的2年生存率显著优于经心尖和经主动脉途径。
- 经颈动脉途径住院时间更短、输血更少、出院回家率更高。
- 三种途径的30天卒中率相似,经颈动脉30天死亡率有更低趋势。
核心结论
- 经颈动脉对比经心尖和经主动脉途径TAVR与更短住院时间、更少输血、更常出院回家及更好2年生存相关。
研究设计与样本
- 回顾性评估165例接受替代途径TAVR患者,经颈动脉84例、经心尖48例、经主动脉33例,分析30天结局和2年Kaplan-Meier生存,使用多变量Cox比例风险模型。
主要发现
- 三组中位STS预测死亡风险相似:经颈动脉9.0%(IQR 6.6-12.0)、经心尖9.1%(IQR 7.0-11.7)、经主动脉10.0%(IQR 8.5-13.0),p=0.14。
- 经颈动脉30天死亡率有更低趋势:3.6%(3/84) vs 6.3%(3/48) vs 15.2%(5/33),p=0.09。
- 经颈动脉2年生存率显著更好:88.4% vs 79.2% vs 63.6%,p=0.004。
- 经颈动脉中位住院时间更短:3.0天(IQR 2.0-5.0) vs 6.5天(IQR 5.0-9.5) vs 7.0天(IQR 5.0-9.0),p<0.001;输血率更低:4.8%(4/84) vs 12.0%(12/48) vs 24.2%(8/33),p<0.001。
- 经颈动脉出院回家无需家庭护理比例更高:89.3%(75/84) vs 54.2%(26/48) vs 42.4%(14/33),p<0.001;30天卒中率相似:2.4%(2/84) vs 2.1%(1/48) vs 3.0%(1/33),p=0.9。
临床怎么用
- 对于不适合经股动脉途径的TAVR患者,经颈动脉途径可作为替代选择,可能改善短期恢复和2年生存。
局限性
- 回顾性研究设计,样本量较小,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter aortic valve replacement (TAVR) using transcarotid access may improve outcomes compared with transapical or transaortic access. METHODS: This study retrospectively evaluated 165 patients who were undergoing alternate access TAVR using transcarotid (n = 84), transapical (n = 48), and transaortic (n = 33) access. The 30-day outcomes and 2-year Kaplan-Meier survival were analyzed using a multivariable Cox proportional hazards model. RESULTS: The median Society of Thoracic Surgeons predicted risk of mortality was similar among patients treated by transcarotid, transapical, and transaortic access (9.0% [interquartile range (IQR), 6.6, 12.0] vs 9.1% [IQR, 7.0, 11.7] vs 10.0% [IQR, 8.5, 13.0]; p = 0.14), respectively. Patients treated with transcarotid TAVR had a trend toward lower 30-day mortality (3.6% [3 of 84] vs 6.3% [3 of 48] vs 15.2% [5 of 33]; p = 0.09) and significantly better 2-year survival (88.4% vs 79.2% vs 63.6%; p = 0.004) compared with patients treated by transapical and transaortic access, respectively. In addition, transcarotid access was associated with a shorter median length of stay (3.0 days [IQR, 2.0, 5.0] vs 6.5 days [IQR. 5.0, 9.5] vs 7.0 days [IQR, 5.0, 9.0]; p < 0.001), lower transfusion rate (4.8% [4 of 84] vs 12.0% [12 of 48] vs 24.2% [8 of 33]; p < 0.001), higher likelihood of discharge to home without home health care (89.3% [75 of 84] vs 54.2% [26 of 48] vs 42.4% [14 of 33]; p < 0.001), and similar 30-day stroke rates (2.4% [2 of 84] vs 2.1% [1 of 48] vs 3.0% [1 of 33];p = 0.9). CONCLUSIONS: Transcarotid compared with transapical and transaortic access for TAVR is associated with shorter length of stay, fewer transfusions, more frequent discharge to home, and better 2-year survival.
引用
- Allen KB, Chhatriwalla AK, Cohen D, et al. Transcarotid Versus Transapical and Transaortic Access for Transcatheter Aortic Valve Replacement. Ann Thorac Surg. 2019. PMID: 30880139. doi:10.1016/j.athoracsur.2019.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。